Similar articles

• Postexposure Doxycycline for Sexually Transmitted Infections. Reply.

  Luetkemeyer AF, Cannon C, Celum C. Luetkemeyer AF, et al. N Engl J Med. 2023 Jul 20;389(3):286-287. doi: 10.1056/NEJMc2306480. N Engl J Med. 2023. PMID: 37467511 No abstract available.
• Total Antimicrobial Consumption in Doxycycline Postexposure Prophylaxis Cohorts and the Intensity of Screening for Bacterial Sexually Transmitted Infections.

  Vanbaelen T, Tsoumanis A, Kenyon C. Vanbaelen T, et al. Clin Infect Dis. 2024 Mar 20;78(3):803-805. doi: 10.1093/cid/ciad553. Clin Infect Dis. 2024. PMID: 37721151 No abstract available.
• Doxycycline Postexposure Prophylaxis for STIs in Women - Uncertain Benefit, Urgent Need.

  Marrazzo J. Marrazzo J. N Engl J Med. 2023 Dec 21;389(25):2389-2390. doi: 10.1056/NEJMe2311948. N Engl J Med. 2023. PMID: 38118030 No abstract available.
• Doxycycline postexposure prophylaxis for prevention of sexually transmitted infections.

  Cannon CA, Celum CL. Cannon CA, et al. Top Antivir Med. 2023 Dec 5;31(5):566-575. Top Antivir Med. 2023. PMID: 38198668 Free PMC article. Review.
• Important considerations regarding the widespread use of doxycycline chemoprophylaxis against sexually transmitted infections.

  Kong FYS, Kenyon C, Unemo M. Kong FYS, et al. J Antimicrob Chemother. 2023 Jul 5;78(7):1561-1568. doi: 10.1093/jac/dkad129. J Antimicrob Chemother. 2023. PMID: 37129293 Free PMC article. Review.